MIM
MCRB icon

Macroview Investment Management’s Seres Therapeutics MCRB Stock Holding History

Macroview Investment Management’s Portfolio MCRB Stock Details MCRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-288
Closed -$8.05K – 678
2023
Q4 		$8.05K Hold
288
– – 0.01% 280
2023
Q3 		$13.7K Sell
288
-101
-26% -$7.71K 0.02% 198
2023
Q2 		$37.3K Buy
389
+101
+35% +$11K 0.06% 95
2023
Q1 		$32.6K Buy
+288
New +$31.2K 0.05% 104

Other funds holding MCRB

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Macroview Investment Management's MCRB Position: Q1 2024 in Review

Macroview Investment Management sold out of Seres Therapeutics (MCRB) in Q1 2024, closing a stake of 288 shares — an estimated $8.05K sold.

Macroview Investment Management first reported a position in MCRB in Q1 2023 and held it in 4 quarters. The position peaked at $37.3K in Q2 2023. 99 funds tracked by Wall St. Rank hold MCRB as of Q1 2024.

  • Macroview Investment Management reported no remaining Seres Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Macroview Investment Management sold 288 Seres Therapeutics shares in Q1 2024, an estimated $8.05K.
  • Macroview Investment Management first reported a position in Seres Therapeutics in Q1 2023 and held it in 4 quarters.
  • Macroview Investment Management's Seres Therapeutics position peaked at $37.3K in Q2 2023.
  • 99 funds tracked by Wall St. Rank held Seres Therapeutics as of Q1 2024.

Based on Macroview Investment Management's 13F filing for Q1 2024, filed 30 Apr 2024.